|Articles|September 1, 2006

Pharmacy Times

  • Volume 0
  • 0

FDA ISSUES ALERTS ON ANTIDEPRESSANT AND MIGRAINE DRUGS

The FDA has asked makersof antidepressants tomodify their labels toinclude data about a rarebut life-threatening lungproblem—persistent pulmonary hypertension—that can affect babies born towomen who take the drugs while pregnant.The agency also issued an alertabout the potential risk of combining antidepressantswith common migrainedrugs. The alert warns that a life-threateningcondition called serotonin syndromemay occur when the drugs are combined.

The FDA is investigating additionalinformation on both risks and will issuefurther updates on the drugs' labels asinformation becomes available. "It isimportant to emphasize that the FDArecommends that women who areexpecting and currently taking antidepressantsshould not discontinue usewithout first talking with a doctor," saidSusan Bro, an FDA spokeswoman.

Articles in this issue

about 19 years ago

Pharmacy Technology Products

about 19 years ago

Tobacco Use

about 19 years ago

Rx Product News

about 19 years ago

OTC Product News

about 19 years ago

can you READ theseRxs?

about 19 years ago

Generic Times Product News

about 19 years ago

compoundingHOTLINE

about 19 years ago

Compounding for Pediatric Patients

about 19 years ago

Police and Drug Testing

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.


Latest CME